Knowthestock.com
DRRX - Durect Corp

Sell

Weak GrowthStock Price Very High

29%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 20.09%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) turning Positive
Net Margin is -1.93%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 5.89
Debt Ratio is 0.15
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.29
Cash Flow is WEAK
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Durect Corp (DRRX) - http://www.durect.com/
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation, COVID-19 patients with acute liver or kidney injury, and non-alcoholic steatohepatitis (NASH). DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (bupivacaine sustained-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery.
Exchange - NASDAQ CAPITAL MARKET
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - James Brown
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.